Fang Ni - Dec 21, 2022 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Officer Title: Chief Business Officer and interim Chief Financial Officer
Signature
Brent Hatzis-Schoch, as Attorney-in-Fact
Stock symbol
BDTX
Transactions as of
Dec 21, 2022
Transactions value $
$72,366
Form type
4
Date filed
12/23/2022, 03:23 PM
Previous filing
Jun 30, 2022
Next filing
Feb 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDTX Common Stock Purchase $25.8K +20K +28.97% $1.29 89K Dec 21, 2022 Direct F1
transaction BDTX Common Stock Purchase $46.6K +36.4K +40.85% $1.28 125K Dec 22, 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.27 to $1.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.3099, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Remarks:

Officer Title: Chief Business Officer and interim Chief Financial Officer